Table 2.
Patient Demographics and Tumor Characteristics (Total n = 135)
| IDH-Mutated | IDH Wild-Type | P-valuea | |
|---|---|---|---|
| Patients, n | 110 | 25 | — |
| Median age at intervention (range) | 38 (13-73) | 52 (20-73) | <.001 |
| Women, n (%) | 50 (45%) | 11 (44%) | .8 |
| Intractable seizures, n (%) | 24 (22%) | 3 (12%) | 0.26 |
| LGG histology, n (%) | |||
| Oligodendroglioma | 70 (64%) | 0 (0%) | |
| 1p19q, n (%) | 67 (96%) | N/A | |
| Astrocytoma | 31 (28%) | 21 (84%) | <.001 |
| Glioma | 0 (0%) | 3 (12%) | |
| Mixed/indeterminate | 9 (8%) | 1 (4%) | |
| Initial surgical intervention, n (%) | |||
| Biopsy | 9 (8%) | 5 (20%) | |
| Subtotal resection | 64 (58%) | 19 (76%) | .003 |
| Gross total resection | 36 (33%) | 1 (4%) | |
| Unknown | 1 (1%) | 0 (0%) | |
| Post-surgical initial management, n (%) | |||
| Observation | 78 (71%) | 9 (36%) | |
| Chemotherapy | 12 (11%) | 0 (0%) | — |
| Radiotherapy | 2 (2%) | 3 (12%) | |
| Concurrent chemoradiation | 18 (16%) | 13 (52%) | |
| BRAF mutation, n (%) | 1 (1%) | — | |
| No mutation | 87 (81%) | 19 (70%) | |
| No data | 20 (18%) | 8 (30%) | |
| Dominant tumor site, n (%) | |||
| Gliomatosis | 0 (0%) | 3 (12%) | <.001 |
| Frontal | 65 (59%) | 5 (20%) | |
| Parietal | 15 (14%) | 1 (4%) | |
| Temporal | 27 (24%) | 16 (64%) | |
| Occipital | 3 (3%) | 0 (0%) |
Abbreviations: IDH, isocitrate dehydrogenase; LGG, low-grade glioma; N/A; not applicable.
aWilcoxon 2-sample test for age comparison. Chi-squared or Fisher exact test where appropriate for categorical comparisons with the exception of intractable seizures. Intractable seizures are compared across IDH groups using Gray’s test in the competing risks setting. Post-surgical initial management was compared across IDH groups using Fisher exact test since dates of treatment were not known in all cases.